Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer

Majida Esslimani-Sahla, Joelle Simony-Lafontaine, Andrew Kramar, Roselyne Lavaill, Caroline Mollevi, Margaret Warner, Jan Åke Gustafsson, Henri Rochefort

Research output: Contribution to journalArticlepeer-review

138 Scopus citations

Abstract

The antiestrogen tamoxifen, a major endocrine therapy of estrogen receptor (ER)-positive breast cancer, is nevertheless inefficient in 30 to 40% of cases for unknown reasons. We retrospectively studied 50 ER-positive primary breast carcinomas. All of the patients had received tamoxifen as the only adjuvant therapy. They were divided into two groups depending on whether they relapsed within 5 years (16 tamoxifen-resistant cases) or did not relapse within 5 years (34 tamoxifen-sensitive cases). The expression of total ERβ protein, and of ERβcx protein, was estimated anonymously in formalin-fixed, paraffin-embedded tumor sections, by using specific antibodies and quantifiying nuclear immunostaining with a computer image analyzer. All of the tumors were found to be HER-2/neu-negative by immunohistochemistry. Univariate analysis showed that Scarff-Bloom-Richardsson grade modified by Elston (SBR grade; P < 0.001), tumor size (P = 0.042), and MIB-1 proliferation index (P = 0.02) were significantly higher in tamoxifen-resistant tumors. A low level of total ERβ, whether in percentage of positive cells or in quantitative immunocytochemical (QIC) score, was also associated with tamoxifen resistance (P = 0.004). ERβcx expression and lymph node status were similar between the two groups. The expression of ERβ in the total population was positively correlated with ERβcx (r = 0.63, P < 0.001), and was independent of the other parameters. In a multivariate analysis, ERβ expression was the most important variable (P = 0.001), followed by SBR grade (I+II versus III; P = 0.008), and MIB-1 (P = 0.016). To conclude, tamoxifen resistance is associated with classical variables of aggressive tumors (high SBR grade, proliferation index, and tumor size) but not with node invasiveness. Low ERβ level is an additional independent marker, better than ERα level, to predict tamoxifen resistance.

Original languageEnglish (US)
Pages (from-to)5769-5776
Number of pages8
JournalClinical Cancer Research
Volume10
Issue number17
DOIs
StatePublished - Sep 1 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer'. Together they form a unique fingerprint.

Cite this